Susquehanna Portfolio Strategies’s KalVista Pharmaceuticals KALV Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-128,011	Closed	-$1.56M	–	1066
2025 Q3	$1.56M	Buy	128,011 +35,752	+39%	+$494K	0.02%	568
2025 Q2	$1.04M	Buy	+92,259	New	+$1.13M	0.02%	499
2024 Q4	–	Sell	-18,338	Closed	-$212K	–	180
2024 Q3	$212K	Hold	18,338	–	–	0.01%	315
2024 Q2	$216K	Hold	18,338	–	–	0.01%	457
2024 Q1	$217K	Hold	18,338	–	–	0.01%	724
2023 Q4	$225K	Buy	+18,338	New	+$167K	﹤0.01%	921

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Susquehanna Portfolio Strategies's KALV Position: Q4 2025 in Review

Susquehanna Portfolio Strategies sold out of KalVista Pharmaceuticals (KALV) in Q4 2025, closing a stake of 128,011 shares — an estimated $1.56M sold.

Susquehanna Portfolio Strategies first reported a position in KALV in Q4 2023 and held it in 6 quarters. The position peaked at $1.56M in Q3 2025. 161 funds tracked by Wall St. Rank hold KALV as of Q4 2025.

Susquehanna Portfolio Strategies reported no remaining KalVista Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Susquehanna Portfolio Strategies sold 128,011 KalVista Pharmaceuticals shares in Q4 2025, an estimated $1.56M.
Susquehanna Portfolio Strategies first reported a position in KalVista Pharmaceuticals in Q4 2023 and held it in 6 quarters.
Susquehanna Portfolio Strategies's KalVista Pharmaceuticals position peaked at $1.56M in Q3 2025.
161 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q4 2025.

Based on Susquehanna Portfolio Strategies's 13F filing for Q4 2025, filed 17 Feb 2026.